Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20798007 | 1.00 | ADORA2A (0.43) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| Phosphoric Acid SCHEMBL1300003 | 0.95 | RNASEL (0.42) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL2458493 | 0.90 | ADORA2A (0.41) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL6685951 | 0.90 | AHCY (0.46) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL1938201 | 0.90 | AHCY (0.46) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL6538264 | 0.88 | ADORA2A (0.57) | ADORA2ALMNAADORA3ADORA1 | |
| SCHEMBL17460351 | 0.87 | PI4KA (0.35) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL2458484 | 0.86 | BLM (0.44) | LMNAADORA3 | |
| SCHEMBL9810700 | 0.85 | ADORA2A (0.41) | ADORA2AADORA2BLMNANT5EHIF1A | |
| SCHEMBL3794703 | 0.84 | PI4KA (0.55) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384635-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | The Broad Institute Inc. (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024086659-A2 | COMPOSITION AND METHODS FOR DETECTING ADENINE MODIFICATIONS | THE UNIVERSITY OF CHICAGO (US) | 2024-04-25 | — | — | WO | claimed |
| US-20240011084-A1 | METHODS FOR FULL-LENGTH REVERSE TRANSCRIPTION PCR OF LONG RNAs CONTAINING MODIFIED RIBONUCLEOSIDES USING A THERMOSTABLE REVERSE TRANSCRIPTASE | NORTHWESTERN UNIVERSITY | 2024-01-11 | — | — | US | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2023018756-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | THE BROAD INSTITUTE, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| WO-2022115822-A2 | METHODS FOR FULL-LENGTH REVERSE TRANSCRIPTION PCR OF LONG RNAS CONTAINING MODIFIED RIBONUCLEOSIDES USING A THERMOSTABLE REVERSE TRANSCRIPTASE | NORTHWESTERN UNIVERSITY (US) | 2022-06-02 | — | — | WO | claimed |
| CN-114076805-A | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-02-22 | — | — | CN | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
| CN-104804903-B | Semiconductor cleaning agent with metal line | 恩特格里斯公司 | 2018-10-30 | — | — | CN | claimed |
| CN-106399506-A | Diagnostic methods for determining prognosis of non-small cell lung cancer | 雅培分子公司 | 2017-02-15 | — | — | CN | claimed |
| EP-2755986-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039857-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2001085220-A1 | LABELED NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | RNA-TEC N.V. (BE) | 2001-11-15 | — | — | WO | claimed |
| JP-57145898-A | — | — | None | — | — | JP | disclosed |
| JP-1083092-A | — | — | None | — | — | JP | disclosed |
| EP-0238672-A1 | PROCESS FOR DEOXIDIZING ALCOHOL | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-09-30 | — | — | EP | disclosed |
| JP-S57145898-A | NOVEL N6, N6-DIMETHYLADENOSINE DERIVATIVE | ARAKAWA CHIYOUTAROU KK | 1982-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | ADORA2A 82/4885ADORA2B 133/4885PI4KA 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.